Propallorphan
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| PubChem CID | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C19H23NO |
| Molar mass | 281.399 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Propallorphan also known by numerous code names, some of the most prominent being RO-1-7780 (RO-7780) and NIH 6045, MCL-117 is an experimental drug of the substituted morphinan family that acts as an opioid antagonist.
Pharmacology
[edit]Pharmacodynamics
[edit]Propallorphan has long been studied as an opioid (i.e., narcotic) antagonist, as confirmed by a 1956 study in which it was first described as RO-1-7780 and was shown to antagonize alphaprodine or morphine in dogs, and alphaprodine in humans. Simultaneous administration of RO-1-7780 with alphaprodine at a dose of 1/75 or 1/100 of the latter appeared to completely reverse the respiratory depression induced in dogs by the narcotic alone. At the same dose ratios of RO-1-7780 to alphaprodine in humans, the antagonist reduced the severity of alphaprodine-induced respiratory depression, while the overall narcotic effect was otherwise considered unchanged.[1] Furthermore, a 1962 study reports that RO-1-7780 reverses the respiratory depressant effects of codeine, although twice the dose is required to achieve the same effect as levallorphan.[2]
In a 1966 study, it was investigated alongside the known opioid antagonist nalorphine as a supplement to thiopental and nitrous oxide anesthesia. RO-1-7780 did not produce the marked respiratory depression observed following morphine administered in the same manner and at the same dose of 1.0 mg/kg.[3] Propallorphan is much weaker in analgesia than the related compound levorphanol; its analgesic activity showed an EC50 of 38.9 mg/kg, with a duration of effect of 226 minutes.[4] Propallorphan acts as a hallucinogen, as evidenced by the fact that its levorotatory isomer induces dysphoria and hallucinations—indeed, producing dysphoric and hallucinogenic effects comparable in intensity to those of nalorphine.[5][6]
References
[edit]- ↑ Marcus PS, Megirian R, White CW (July 1956). "RO-1-7780, a potent antagonist of alphaprodine". Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine. 92 (3). New York, N.Y.: SAGE Publications: 512–515. doi:10.3181/00379727-92-22528. PMID 13359450.
- ↑ Anand Rao D, Hofmann H (1962-01-01). "Influence of (-)3-hydroxy-N-propargyl-morphinan on the respiratory depressant action of codeine". Experientia. 18 (1): 7–8. doi:10.1007/BF02136626. ISSN 0014-4754.
- ↑ Keats AS, Telford J (January 1966). "Studies of analgesic drugs. X. Respiratory effects of narcotic antagonists". The Journal of Pharmacology and Experimental Therapeutics. 151 (1): 126–132. doi:10.1016/s0022-3565(25)27235-4. PMID 5902169.
- ↑ Eddy NB, Halbach H, Braenden OJ (1956). "Synthetic substances with morphine-like effect; relationship between analgesic action and addiction liability, with a discussion of the chemical structure of addiction-producing substances". Bulletin of the World Health Organization. 14 (3): 353–402. PMC 2538049. PMID 13342924.
- ↑ Musacchio JM, Klein M, Canoll PD (1989). "Dextromethorphan and sigma ligands: common sites but diverse effects". Life Sciences. 45 (19): 1721–1732. doi:10.1016/0024-3205(89)90510-9. PMID 2556614.
- ↑ Musacchio JM (June 1990). "The psychotomimetic effects of opiates and the sigma receptor". Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology. 3 (3): 191–200. PMID 2163646.